Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?
BACKGROUND
Introduction of the 7-valent pneumococcal conjugate vaccine (7vCRM) in several countries has led to a rapid, significant drop in vaccine-type invasive pneumococcal disease (IPD) in immunized children. In the United States and some other countries with high antibiotic use, a subsequent rise in serotype 19A IPD has been taken to indicate that the 19F conjugate in the vaccine provides no cross-protection against the immunologically related 19A.


CONCLUSIONS
We systematically assessed the clinical efficacy and effectiveness of 19F-containing vaccines against 19A disease or nasopharyngeal carriage by searching English-language articles in the electronic databases PubMed, Current contents, Scopus, and Embase from 1985 to 2008. The vaccine efficacy and effectiveness point estimates were consistently positive for modest protection against 19A IPD and acute otitis media (AOM). However, statistical significance was not reached in any individual study. No consistent impact of 7vCRM on 19A nasopharyngeal colonization could be detected. These findings are discussed in context of immunogenicity analyses indicating that 7vCRM induces functionally active anti-19A antibodies after the booster dose, and that other 19F-containing vaccine formulations may elicit higher levels of such antibodies after both primary and booster doses.


CONCLUSIONS
Taken together, these results suggest that 19F-conjugates can provide some protection against 19A disease. The magnitude of this protection in a given setting will likely depend on several factors. These include the anti-19A immunogenicity of the specific vaccine formulation, the number of doses of that formulation needed to elicit the response, and the burden of 19A disease that occurs after those doses. It is possible that a modest protective effect may be obscured by the presence of countervailing selection pressures (such as high antibiotic use) that favor an increase in colonization with antibiotic-non-susceptible strains of 19A.
Hausdorff
William P
WP
GlaxoSmithKline Biologicals, Rixensart, Belgium. william.p.hausdorff@gskbio.com
Hoet
Bernard
B
Schuerman
Lode
L
D000208:Acute Disease; D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000276:immunology; D002353:Carrier State / Q000517:prevention & control; D003429:Cross Reactions; D004363:Drug Utilization; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D009305:Nasopharynx / Q000382:microbiology; D010033:Otitis Media / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000276:immunology*; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification / Q000276:immunology* / Q000302:isolation & purification; D014481:United States / Q000453:epidemiology; D018074:Vaccines, Conjugate / Q000276:immunology
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate